全国服务咨询热线：
18438616290
18438616290
产品分类
Product Category详细介绍
| 品牌 | absin | CAS | 54-85-3 |
|---|---|---|---|
| 分子式 | C6H7N3O | 纯度 | 99% |
| 分子量 | 137.14 | 货号 | abs47027420 |
| 规格 | 25mg | 供货周期 | 现货 |
| 主要用途 | used primarily as a tuberculostatic | 应用领域 | 化工,生物产业,农林牧渔,制药/生物制药,综合 |
Isoniazid 54-85-3
| 产品描述 | |
| 描述 | Isoniazid is an?antibacterial?agent used primarily as a tuberculostatic. |
| 纯度 | 99% |
| 储存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 别名 | 异yan肼；INH；Isonicotinic acid hydrazide；Isonicotinic hydrazide |
| 外观 | 白色或类白色结晶性粉末 |
| 可溶性/溶解性 | DMSO : 26 mg/mL (189.6 mM) Ethanol : 26 mg/mL (189.6 mM) Water : 25 mg/mL (182.3 mM) |
| 生物活性 | |
| In vitro(体外研究) | Isoniazid is a prodrug that requires activation by the mycobacterial catalase-peroxidase enzyme (KatG) to an active form that then exerts a lethal effect on an intracellular target or targets. Isoniazid upregulates the expression of an operon containing five FAS II components, including kasA and acpM. Isoniazid results in the accumulation of ACP-bound lipid precursors to mycolic acids that are 26 carbons long and fully saturated. Isoniazid enters the mycobacterial cell by passive diffusion. Isoniazid itself is not toxic to the bacterial cell, but acts as a prodrug and is activated by the mycobacterial enzyme KatG, a multifunctional catalase-peroxidase that has other activities, including peroxynitritase and NADH oxidase. Isoniazid inhibits cell wall lipid synthesis, coupled with the findings that inhibitory INH adducts of NAD+/NADP+ are formed from the isonicotinoyl radical, leading the field away from this area. Isoniazid induces a concentration-dependent (0-40 mM) cytotoxic effect in day-1 treated HepG2 cells and not significantly affected by decreases in intracellular GSH concentrations. |
| In vivo(体内研究) | Isoniazid increases CYP2E1 protein, and the 6-hydroxychlorzoxazone formation rate is increased by 2.7 and 2.2-fold in liver and kidney, respectively. Isoniazid decreases liver and kidney 20-HETE content to 34% and 15.6% of control, respectively, without significantly altering tissue 19-HETE concentration. |
| 参考文献 | |
| 参考文献 |
|
| 研究领域 | |
| 研究领域 | Drug DiscoverySmall Molecule DrugLead Compound Discovery |
产品咨询
地址：上海市浦东新区新浩路58号申江科创园18栋
邮箱：lanwu@univ-bio.com
传真：